- IMvigor011 showed Tecentriq reduced disease‑free survival risk by 36% and overall mortality by 41% in ctDNA‑positive MIBC patients.
- Study surveillance enrolled 761 patients with serial ctDNA testing up to one year post‑cystectomy; 250 ctDNA‑positive patients entered the randomized treatment phase.
- FDA approved atezolizumab (Tecentriq) and Tecentriq Hybreza (atezolizumab + hyaluronidase‑tqjs) as adjuvant ctDNA MRD‑guided therapy and authorized Natera's Signatera CDx as the companion diagnostic.
FDA approval
The FDA approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase‑tqjs) as adjuvant treatment for adult muscle‑invasive bladder cancer (MIBC) patients with circulating tumor DNA (ctDNA) molecular residual disease (MRD) detected after cystectomy, using Natera’s Signatera CDx as the companion diagnostic.
Key trial outcomes
Approval was based on Phase III IMvigor011, which reported a 36% reduction in risk of disease recurrence or death (DFS) and a 41% reduction in risk of death (OS) among patients with detectable ctDNA identified via serial testing within one year of cystectomy; the safety profile was consistent with previous Tecentriq studies.
Study design and testing
IMvigor011 was a global, randomized, placebo‑controlled, double‑blind trial; its surveillance phase enrolled 761 patients who underwent serial ctDNA testing up to one year post‑surgery, of whom 250 ctDNA‑positive patients entered the randomized treatment phase; the primary endpoint was investigator‑assessed DFS, with OS and tolerability among the secondary endpoints.
Clinical implications
The decision establishes the first regulatory approval of a ctDNA‑guided adjuvant therapy in MIBC, enabling selective deployment of immunotherapy for patients with molecular evidence of residual disease while sparing those without ctDNA from additional treatment.
